Literature DB >> 27753449

Cross-sectional study on allergic sensitization of Austrian adolescents using molecule-based IgE profiling.

T Stemeseder1, E Klinglmayr1, S Moser2,3, L Lueftenegger4,5, R Lang4, M Himly1, G J Oostingh5, J Zumbach2, A C Bathke6, T Hawranek4, G Gadermaier1.   

Abstract

BACKGROUND: Allergen-specific IgE antibodies are a hallmark of type I allergy. The aim of this cross-sectional study was to analyze the sensitization profiles of an Austrian adolescent population utilizing molecule-based IgE diagnosis.
METHODS: Serum samples of 501 nonselected pupils from Salzburg, Austria, were tested in ImmunoCAP ISAC® for IgE reactivity to 112 single allergens. Sensitization profiles were assessed and statistically coordinated with reported allergies.
RESULTS: In the population aged 12-21 years, 53.5% showed IgE reactivity to at least one allergen tested. The highest prevalence was found for Phl p 1 from grass pollen (26.5%), group 2 mite allergens (18.2%), Bet v 1 from birch pollen (16.3%) and Fel d 1 from cat (14.4%). The majority of participants showed a complex sensitization profile and reacted on average to 9 allergens. Pollen sensitization was highly prevalent (41.7%) and mainly driven by group I grass and PR-10 allergens of the Betulaceae family, while Pla l 1 represented the most relevant weed. Diagnosed and self-reported allergies were noted in 21.9% and 45.5% of participants, respectively, and correlated well with in vitro results. Among atopic individuals, 71.4% reported to suffer from at least one allergy; concordance was found for grass and cat sensitization, while venom- and weed pollen-positive individuals were frequently asymptomatic.
CONCLUSIONS: More than half of the tested adolescent population had already established an atopic status presenting a complex IgE reactivity profile dominated by pollen sensitization. Detailed molecule-based analysis allows determining relevant biomarkers and monitoring of the atopic status in populations.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  IgE; allergen microarray; epidemiology; molecule-based diagnosis; sensitization

Mesh:

Substances:

Year:  2016        PMID: 27753449     DOI: 10.1111/all.13071

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  17 in total

Review 1.  Prevalence of sensitization to molecular food allergens in Europe: A systematic review.

Authors:  Daniil Lisik; Athina Ioannidou; Giulia Spolidoro; Mohamed Ali; Sungkutu Nyassi; Yohanes Amera; Graciela Rovner; Ekaterina Khaleva; Carina Venter; Ronald van Ree; Margitta Worm; Berber Vlieg-Boerstra; Aziz Sheikh; Antonella Muraro; Graham Roberts; Bright I Nwaru
Journal:  Clin Transl Allergy       Date:  2022-07-06       Impact factor: 5.657

2.  IgE antibodies increase honeybee venom responsiveness and detoxification efficiency of mast cells.

Authors:  Philipp Starkl; Nicolas Gaudenzio; Thomas Marichal; Laurent L Reber; Riccardo Sibilano; Martin L Watzenboeck; Frédéric Fontaine; André C Mueller; Mindy Tsai; Sylvia Knapp; Stephen J Galli
Journal:  Allergy       Date:  2021-05-06       Impact factor: 14.710

3.  Exposure to Indoor Allergens in Different Residential Settings and Its Influence on IgE Sensitization in a Geographically Confined Austrian Cohort.

Authors:  Teresa Stemeseder; Bettina Schweidler; Patrick Doppler; Eva Klinglmayr; Stephanie Moser; Lisa Lueftenegger; Martin Himly; Roland Lang; Joerg Zumbach; Gertie J Oostingh; Thomas Hawranek; Arne C Bathke; Gabriele Gadermaier
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

4.  Conjugation of wildtype and hypoallergenic mugwort allergen Art v 1 to flagellin induces IL-10-DC and suppresses allergen-specific TH2-responses in vivo.

Authors:  Stefan Schülke; Kirsten Kuttich; Sonja Wolfheimer; Nadine Duschek; Andrea Wangorsch; Andreas Reuter; Peter Briza; Isabel Pablos; Gabriele Gadermaier; Fatima Ferreira; Stefan Vieths; Masako Toda; Stephan Scheurer
Journal:  Sci Rep       Date:  2017-09-18       Impact factor: 4.379

Review 5.  Nanomaterials in the Context of Type 2 Immune Responses-Fears and Potentials.

Authors:  Martin Himly; Robert Mills-Goodlet; Mark Geppert; Albert Duschl
Journal:  Front Immunol       Date:  2017-04-25       Impact factor: 7.561

6.  In vitro evidence of efficacy and safety of a polymerized cat dander extract for allergen immunotherapy.

Authors:  María Morales; Mayte Gallego; Victor Iraola; Marta Taulés; Eliandre de Oliveira; Raquel Moya; Jerónimo Carnés
Journal:  BMC Immunol       Date:  2017-02-24       Impact factor: 3.615

7.  Can the Pattern of Early Sensitization to Allergen Molecules Drive a New Approach for Prevention of Allergy?

Authors:  Cristoforo Incorvaia; Irene Martignago; Erminia Ridolo
Journal:  EBioMedicine       Date:  2017-11-22       Impact factor: 8.143

8.  IgE Effector Mechanisms, in Concert with Mast Cells, Contribute to Acquired Host Defense against Staphylococcusaureus.

Authors:  Philipp Starkl; Martin L Watzenboeck; Lauren M Popov; Sophie Zahalka; Anastasiya Hladik; Karin Lakovits; Mariem Radhouani; Arvand Haschemi; Thomas Marichal; Laurent L Reber; Nicolas Gaudenzio; Riccardo Sibilano; Lukas Stulik; Frédéric Fontaine; André C Mueller; Manuel R Amieva; Stephen J Galli; Sylvia Knapp
Journal:  Immunity       Date:  2020-09-09       Impact factor: 43.474

9.  Sensitization to PR-10 proteins is indicative of distinctive sensitization patterns in adults with a suspected food allergy.

Authors:  Mark A Blankestijn; André C Knulst; Edward F Knol; Thuy-My Le; Heike Rockmann; Henny G Otten; Rob J B Klemans
Journal:  Clin Transl Allergy       Date:  2017-11-23       Impact factor: 5.871

10.  Distinct epitope structures of defensin-like proteins linked to proline-rich regions give rise to differences in their allergenic activity.

Authors:  I Pablos; S Eichhorn; Y Machado; P Briza; A Neunkirchner; B Jahn-Schmid; S Wildner; W T Soh; C Ebner; J-W Park; W F Pickl; N Arora; S Vieths; F Ferreira; G Gadermaier
Journal:  Allergy       Date:  2017-09-27       Impact factor: 13.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.